The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。